Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab + MEDI0680 in aggressive B-cell lymphoma
NCT02271945Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of inebilizumab and MEDI0680 in aggressive B-cell lymphoma (2 arms), sponsored by MedImmune. Primary endpoints: Maximum Tolerated Dose, Treatment-Emergent Adverse Events and 3 more. Started Dec 2014; status: completed.
02
Drugs
inebilizumabMEDI0680
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT02271945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271945.